SK286245B6 - Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu - Google Patents

Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu Download PDF

Info

Publication number: SK286245B6
Authority: SK; Slovakia
Prior art keywords: composition; ziprasidone; particle size; mean; free base
Prior art date: 1998-06-15

Application number

SK769-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK76999A3 (en

Inventor

Frank Robert Busch

Angela Carol Gatlin Hausberger

Bijan Rasadi

Daniel Ray Arenson

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-15

Filing date

1999-06-09

Publication date

2008-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286245(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-06-09 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2000-12-11 Publication of SK76999A3 publication Critical patent/SK76999A3/sk

2008-06-06 Publication of SK286245B6 publication Critical patent/SK286245B6/sk

Links

229960000607 ziprasidone Drugs 0.000 title claims abstract description 70
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title claims abstract description 70
ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical compound [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 title claims abstract description 58
239000013078 crystal Substances 0.000 title claims abstract description 22
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 6
238000004519 manufacturing process Methods 0.000 title abstract description 9
239000002245 particle Substances 0.000 claims abstract description 95
239000000203 mixture Substances 0.000 claims abstract description 87
239000012458 free base Substances 0.000 claims abstract description 37
229960003474 ziprasidone hydrochloride Drugs 0.000 claims abstract description 34
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
238000011282 treatment Methods 0.000 claims abstract description 11
239000002904 solvent Substances 0.000 claims abstract description 7
208000028017 Psychotic disease Diseases 0.000 claims abstract description 6
239000003085 diluting agent Substances 0.000 claims abstract description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 34
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
238000000034 method Methods 0.000 claims description 27
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 17
238000010992 reflux Methods 0.000 claims description 13
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
238000000149 argon plasma sintering Methods 0.000 claims description 5
239000000872 buffer Substances 0.000 claims description 5
238000010438 heat treatment Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 2
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 abstract 1
239000002775 capsule Substances 0.000 description 43
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
238000009472 formulation Methods 0.000 description 17
239000000725 suspension Substances 0.000 description 16
238000004090 dissolution Methods 0.000 description 14
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
239000002552 dosage form Substances 0.000 description 12
210000002966 serum Anatomy 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
235000019359 magnesium stearate Nutrition 0.000 description 9
238000012360 testing method Methods 0.000 description 9
239000002609 medium Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000003556 assay Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000002585 base Substances 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 5
229960001021 lactose monohydrate Drugs 0.000 description 5
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
235000021152 breakfast Nutrition 0.000 description 4
235000014121 butter Nutrition 0.000 description 4
238000002425 crystallisation Methods 0.000 description 4
239000012738 dissolution medium Substances 0.000 description 4
239000000945 filler Substances 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
238000002156 mixing Methods 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
238000002414 normal-phase solid-phase extraction Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
235000019759 Maize starch Nutrition 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010019160 Pancreatin Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
244000061456 Solanum tuberosum Species 0.000 description 2
235000002595 Solanum tuberosum Nutrition 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
235000015241 bacon Nutrition 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
239000008119 colloidal silica Substances 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000013601 eggs Nutrition 0.000 description 2
238000010828 elution Methods 0.000 description 2
238000011049 filling Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
150000004682 monohydrates Chemical class 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
229940055695 pancreatin Drugs 0.000 description 2
239000012071 phase Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
235000012015 potatoes Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
238000010998 test method Methods 0.000 description 2
235000008939 whole milk Nutrition 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
241000206672 Gelidium Species 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000007958 cherry flavor Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009506 drug dissolution testing Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000003134 recirculating effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000000790 scattering method Methods 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
230000005476 size effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
239000012798 spherical particle Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Detergent Compositions (AREA)
Feeding Of Articles By Means Other Than Belts Or Rollers (AREA)
Polyamides (AREA)

SK769-99A 1998-06-15 1999-06-09 Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu SK286245B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8922998P	1998-06-15	1998-06-15

Publications (2)

Publication Number	Publication Date
SK76999A3 SK76999A3 (en)	2000-12-11
SK286245B6 true SK286245B6 (sk)	2008-06-06

Family

ID=22216447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK769-99A SK286245B6 (sk)	1998-06-15	1999-06-09	Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu

Country Status (45)

Country	Link
US (1)	US6150366A (uk)
EP (1)	EP0965343B1 (uk)
JP (2)	JP3441676B2 (uk)
KR (1)	KR100338915B1 (uk)
CN (1)	CN1307994C (uk)
AP (1)	AP1216A (uk)
AR (1)	AR015553A1 (uk)
AT (1)	ATE240732T1 (uk)
AU (1)	AU753820B2 (uk)
BG (1)	BG64691B1 (uk)
BR (1)	BR9902268A (uk)
CA (1)	CA2274338C (uk)
CO (1)	CO5070579A1 (uk)
CY (1)	CY2003002I1 (uk)
CZ (1)	CZ297954B6 (uk)
DE (1)	DE69908021T2 (uk)
DK (1)	DK0965343T3 (uk)
EA (1)	EA002223B1 (uk)
ES (1)	ES2197581T3 (uk)
GT (1)	GT199900080A (uk)
HK (1)	HK1024184A1 (uk)
HN (1)	HN1999000089A (uk)
HR (1)	HRP990193B1 (uk)
HU (1)	HU226487B1 (uk)
ID (1)	ID23546A (uk)
IL (1)	IL130424A (uk)
IS (1)	IS2182B (uk)
MA (1)	MA26647A1 (uk)
MY (1)	MY121397A (uk)
NO (1)	NO316713B1 (uk)
NZ (1)	NZ336271A (uk)
OA (1)	OA11064A (uk)
PA (1)	PA8475601A1 (uk)
PE (1)	PE20000632A1 (uk)
PL (2)	PL195209B1 (uk)
PT (1)	PT965343E (uk)
RS (1)	RS49611B (uk)
SG (1)	SG77243A1 (uk)
SI (1)	SI0965343T1 (uk)
SK (1)	SK286245B6 (uk)
TR (1)	TR199901379A2 (uk)
TW (1)	TW590774B (uk)
UA (1)	UA59383C2 (uk)
UY (1)	UY25649A1 (uk)
ZA (1)	ZA993938B (uk)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080113025A1 (en) *	1998-11-02	2008-05-15	Elan Pharma International Limited	Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7175855B1 (en)	1999-05-27	2007-02-13	Pfizer Inc.	Ziprasidone suspension
DE60001649T2 (de) *	1999-05-27	2003-08-21	Pfizer Prod Inc	Ziprasidonsuspension
CA2389235C (en)	1999-10-29	2007-07-17	Euro-Celtique, S.A.	Controlled release hydrocodone formulations
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
CN101653411A (zh)	2000-10-30	2010-02-24	欧罗赛铁克股份有限公司	控释氢可酮制剂
UY27668A1 (es) *	2002-02-20	2003-10-31	Pfizer Prod Inc	Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) *	2002-02-20	2004-03-11	Pfizer Inc.	Ziprasidone composition and synthetic controls
WO2003097046A1 (en) *	2002-05-17	2003-11-27	Duke University	Method for treating obesity
US7488729B2 (en) *	2002-12-04	2009-02-10	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (en) *	2002-12-04	2004-06-17	Dr. Reddy's Laboratories Limited	Polymorphic forms of ziprasidone and its hydrochloride
US20050143396A1 (en) *	2003-04-11	2005-06-30	Hertero Drugs Limited	Novel crystalline forms of ziprasidone hydrochloride
EP2316456B1 (en)	2003-04-29	2017-06-14	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
KR20060015750A (ko) *	2003-06-03	2006-02-20	테바 파마슈티컬 인더스트리즈 리미티드	지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
US20050049295A1 (en) *	2003-06-12	2005-03-03	Dr. Reddy's Laboratories Limited	Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
RU2351316C2 (ru) *	2003-09-02	2009-04-10	Пфайзер Продактс Инк.	Лекарственные формы с замедленным высвобождением зипразидона
US7667037B2 (en) *	2003-10-24	2010-02-23	Teva Pharmaceutical Industries Ltd.	Processes for preparation of ziprasidone
AU2003285600A1 (en) *	2003-11-28	2005-06-24	Siddiqui Mohammed Jaweed Mukarram	Process for the preparing ziprasidone monohydrochloride hydrate
WO2005061493A2 (en)	2003-12-18	2005-07-07	Teva Pharmaceutical Industries Ltd.	Polymorphic form b2 of ziprasidone base
WO2005065660A2 (en) *	2003-12-31	2005-07-21	Alpharma, Inc.	Ziprasidone formulations
BRPI0506829A (pt) *	2004-01-13	2007-05-29	Univ Duke	composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
DE602005018171D1 (de) *	2004-02-27	2010-01-21	Ranbaxy Lab Ltd	Verfahren zur herstellung von ziprasidon
CA2565154A1 (en) *	2004-05-03	2005-11-24	Duke University	Compositions for affecting weight loss
WO2005107719A2 (en) *	2004-05-06	2005-11-17	Sandoz Ag	Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) *	2004-05-14	2010-08-24	Apotex Pharmachem Inc.	New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) *	2004-06-11	2005-12-29	Dr. Reddy's Laboratories Ltd.	Ziprasidone dosage form
CA2471219A1 (en) *	2004-06-14	2005-12-14	Apotex Pharmachem Inc.	Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) *	2004-08-27	2015-06-02	University Of Kentucky Research Foundation	Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
US20090142404A1 (en) *	2004-08-31	2009-06-04	Pfizer Inc	Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
JP5324098B2 (ja) *	2004-11-16	2013-10-23	アルケルメスファーマアイルランドリミテッド	注射可能なナノ粒子のオランザピン製剤
US20080268034A1 (en) *	2005-01-07	2008-10-30	Girish Karanth	Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) *	2005-02-08	2010-07-06	Ash Access Technology, Inc.	Catheter lock solution comprising citrate and a paraben
WO2006086779A1 (en) *	2005-02-11	2006-08-17	Teva Pharmaceutical Industries Ltd.	Amorphous ziprasidone mesylate
ITMI20050346A1 (it)	2005-03-07	2006-09-08	Dipharma Spa	Forma solida di ziprasidone cloridrato
CA2500667C (en) *	2005-03-11	2013-01-15	Apotex Pharmachem Inc.	Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
CA2599391A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) *	2005-03-14	2006-09-21	Teva Pharmaceutical Industries Ltd.	Anhydrous ziprasidone mesylate and a process for its preparation
NZ561950A (en) *	2005-04-13	2010-09-30	Pfizer Prod Inc	Injectable depot formulations comprising ziprasidone in nanoparticle form with two surface stabilizers
US20080305161A1 (en) *	2005-04-13	2008-12-11	Pfizer Inc	Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
CA2605447A1 (en) *	2005-04-22	2006-11-02	Wyeth	Therapeutic combinations for the treatment or prevention of psychotic disorders
KR101380088B1 (ko)	2005-05-26	2014-04-10	다이닛본 스미토모 세이야꾸 가부시끼가이샤	약학 조성물
CN101242813A (zh) *	2005-06-20	2008-08-13	依兰药物国际有限公司	包含芳基-杂环化合物的毫微粒和控制释放组合物
CA2613474A1 (en) *	2005-06-20	2007-03-08	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
JP5180092B2 (ja)	2005-11-22	2013-04-10	オレキシジェン・セラピューティクス・インコーポレーテッド	インスリン感受性を増すための組成物および方法
DK1954241T3 (da) *	2005-11-28	2012-06-18	Orexigen Therapeutics Inc	Zonisamid-formulering med vedvarende frigivelse
PL379569A1 (pl) *	2006-04-28	2007-10-29	Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna	Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
EP1892243A1 (en) *	2006-08-02	2008-02-27	KRKA, tovarna zdravil, d.d., Novo mesto	Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) *	2006-08-02	2008-03-05	Krka	Polymorphic forms of ziprasidone sulphates
KR101654176B1 (ko)	2006-11-09	2016-09-09	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
US20080286373A1 (en) *	2007-05-18	2008-11-20	Palepu Nageswara R	Ziprasidone formulations
EP2197446A4 (en) *	2007-08-31	2012-01-25	Reddys Lab Ltd Dr	PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
US8410268B2 (en) *	2008-03-11	2013-04-02	Alkem Laboratories Limited	Process for the preparation of ziprasidone
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
DE102008045854A1 (de)	2008-09-05	2010-03-11	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
CA2937222C (en) *	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
EP2340834A1 (en)	2009-12-30	2011-07-06	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Enhanced Solubility of Ziprasidone
KR101841442B1 (ko)	2010-01-11	2018-03-23	오렉시젠 세러퓨틱스 인크.	주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
SI3257500T1 (sl)	2010-02-25	2019-12-31	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Formulacije apiksabana
WO2011148253A2 (en)	2010-05-25	2011-12-01	Aurobindo Pharma Limited	Solid dosage forms of antipsychotics
SI23610A (sl)	2011-01-13	2012-07-31	Diagen@d@o@o	Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
RS63569B1 (sr)	2012-06-06	2022-10-31	Nalpropion Pharmaceuticals Llc	Ompozicija za upotrebu u metodi lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom
CA2891122C (en)	2012-11-14	2021-07-20	The Johns Hopkins University	Methods and compositions for treating schizophrenia
CA3092335A1 (en)	2018-03-05	2019-09-12	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5264446A (en) *	1980-09-09	1993-11-23	Bayer Aktiengesellschaft	Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) *	1987-03-02	1994-02-23	Pfizer	Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) *	1988-01-22	1989-11-28	Pfizer Inc.	Piperazinyl-heterocyclic compounds
DE4141268A1 (de) *	1991-12-14	1993-06-17	Merck Patent Gmbh	Pharmazeutische zubereitung
US5338846A (en) *	1992-08-26	1994-08-16	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) *	1993-06-28	1994-10-25	Pfizer Inc.	Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
EP0790236B1 (en) *	1996-02-13	2003-11-19	Pfizer Inc.	Pro-drugs of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
ATE364374T1 (de) *	1997-08-11	2007-07-15	Pfizer Prod Inc	Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit

1999
- 1999-05-27 US US09/320,985 patent/US6150366A/en not_active Expired - Lifetime
- 1999-06-04 HN HN1999000089A patent/HN1999000089A/es unknown
- 1999-06-08 AT AT99304451T patent/ATE240732T1/de active
- 1999-06-08 PT PT99304451T patent/PT965343E/pt unknown
- 1999-06-08 DK DK99304451T patent/DK0965343T3/da active
- 1999-06-08 ES ES99304451T patent/ES2197581T3/es not_active Expired - Lifetime
- 1999-06-08 SI SI9930316T patent/SI0965343T1/xx unknown
- 1999-06-08 EP EP99304451A patent/EP0965343B1/en not_active Expired - Lifetime
- 1999-06-08 DE DE69908021T patent/DE69908021T2/de not_active Expired - Lifetime
- 1999-06-08 GT GT199900080A patent/GT199900080A/es unknown
- 1999-06-09 TW TW088109645A patent/TW590774B/zh not_active IP Right Cessation
- 1999-06-09 AU AU33983/99A patent/AU753820B2/en not_active Ceased
- 1999-06-09 SK SK769-99A patent/SK286245B6/sk not_active IP Right Cessation
- 1999-06-10 SG SG1999002794A patent/SG77243A1/en unknown
- 1999-06-10 AP APAP/P/1999/001579A patent/AP1216A/en active
- 1999-06-10 IL IL13042496A patent/IL130424A/xx not_active IP Right Cessation
- 1999-06-11 MY MYPI99002412A patent/MY121397A/en unknown
- 1999-06-11 TR TR1999/01379A patent/TR199901379A2/xx unknown
- 1999-06-11 PE PE1999000523A patent/PE20000632A1/es not_active Application Discontinuation
- 1999-06-11 IS IS5079A patent/IS2182B/is unknown
- 1999-06-11 CA CA002274338A patent/CA2274338C/en not_active Expired - Lifetime
- 1999-06-11 AR ARP990102822A patent/AR015553A1/es active IP Right Grant
- 1999-06-14 ZA ZA9903938A patent/ZA993938B/xx unknown
- 1999-06-14 HR HR990193A patent/HRP990193B1/xx not_active IP Right Cessation
- 1999-06-14 RS YUP-271/99A patent/RS49611B/sr unknown
- 1999-06-14 PL PL333737A patent/PL195209B1/pl not_active IP Right Cessation
- 1999-06-14 PA PA19998475601A patent/PA8475601A1/es unknown
- 1999-06-14 OA OA9900126A patent/OA11064A/en unknown
- 1999-06-14 KR KR1019990021977A patent/KR100338915B1/ko not_active IP Right Cessation
- 1999-06-14 NO NO19992892A patent/NO316713B1/no not_active IP Right Cessation
- 1999-06-14 HU HU9901960A patent/HU226487B1/hu not_active IP Right Cessation
- 1999-06-14 CN CNB991111192A patent/CN1307994C/zh not_active Expired - Fee Related
- 1999-06-14 JP JP16677399A patent/JP3441676B2/ja not_active Expired - Lifetime
- 1999-06-14 PL PL380276A patent/PL195606B1/pl not_active IP Right Cessation
- 1999-06-14 UA UA99063279A patent/UA59383C2/uk unknown
- 1999-06-14 CZ CZ0212799A patent/CZ297954B6/cs not_active IP Right Cessation
- 1999-06-14 NZ NZ336271A patent/NZ336271A/xx not_active IP Right Cessation
- 1999-06-14 ID IDP990571D patent/ID23546A/id unknown
- 1999-06-14 MA MA25621A patent/MA26647A1/fr unknown
- 1999-06-14 BG BG103489A patent/BG64691B1/bg unknown
- 1999-06-15 EA EA199900467A patent/EA002223B1/ru not_active IP Right Cessation
- 1999-06-15 CO CO99037319A patent/CO5070579A1/es unknown
- 1999-06-15 BR BR9902268-0A patent/BR9902268A/pt not_active Application Discontinuation
- 1999-08-10 UY UY25649A patent/UY25649A1/es unknown
2000
- 2000-06-16 HK HK00103630A patent/HK1024184A1/xx not_active IP Right Cessation
2001
- 2001-06-11 JP JP2001175276A patent/JP4187423B2/ja not_active Expired - Lifetime
2003
- 2003-11-20 CY CY200300002C patent/CY2003002I1/el unknown

Also Published As

Publication number	Publication date
IL130424A0 (en)	2000-06-01
PL195209B1 (pl)	2007-08-31
EA199900467A2 (ru)	1999-12-29
ID23546A (id)	2000-05-04
ES2197581T3 (es)	2004-01-01
JP3441676B2 (ja)	2003-09-02
CO5070579A1 (es)	2001-08-28
PA8475601A1 (es)	2000-09-29
KR100338915B1 (ko)	2002-05-30
AP1216A (en)	2003-10-19
TW590774B (en)	2004-06-11
HU226487B1 (en)	2009-03-02
IS2182B (is)	2006-12-15
GT199900080A (es)	2000-11-29
AR015553A1 (es)	2001-05-02
HU9901960D0 (en)	1999-08-30
NO992892D0 (no)	1999-06-14
EA199900467A3 (ru)	2000-04-24
SI0965343T1 (en)	2003-10-31
PL333737A1 (en)	1999-12-20
OA11064A (en)	2002-03-13
EP0965343A3 (en)	2000-02-23
CA2274338C (en)	2003-04-15
DE69908021D1 (de)	2003-06-26
RS49611B (sr)	2007-06-04
SK76999A3 (en)	2000-12-11
AU3398399A (en)	1999-12-23
SG77243A1 (en)	2000-12-19
YU27199A (sh)	2002-12-10
UY25649A1 (es)	2000-02-23
HRP990193A2 (en)	2000-02-29
CY2003002I1 (el)	2009-11-04
PT965343E (pt)	2003-08-29
BG103489A (en)	2000-07-31
EP0965343A2 (en)	1999-12-22
PL195606B1 (pl)	2007-10-31
HUP9901960A2 (hu)	2000-08-28
CA2274338A1 (en)	1999-12-15
JP4187423B2 (ja)	2008-11-26
PE20000632A1 (es)	2000-07-26
EA002223B1 (ru)	2002-02-28
CZ297954B6 (cs)	2007-05-09
ZA993938B (en)	2000-12-14
JP2000007566A (ja)	2000-01-11
MY121397A (en)	2006-01-28
HN1999000089A (es)	1999-11-03
CZ212799A3 (cs)	2000-09-13
JP2002003492A (ja)	2002-01-09
ATE240732T1 (de)	2003-06-15
NO992892L (no)	1999-12-16
CN1307994C (zh)	2007-04-04
IS5079A (is)	1999-12-16
IL130424A (en)	2003-10-31
CN1242987A (zh)	2000-02-02
NZ336271A (en)	2000-10-27
EP0965343B1 (en)	2003-05-21
BR9902268A (pt)	2000-05-02
BG64691B1 (bg)	2005-12-30
DK0965343T3 (da)	2003-08-04
HK1024184A1 (en)	2000-10-05
NO316713B1 (no)	2004-04-13
HUP9901960A3 (en)	2000-09-28
UA59383C2 (uk)	2003-09-15
DE69908021T2 (de)	2003-11-27
US6150366A (en)	2000-11-21
KR20000006143A (ko)	2000-01-25
TR199901379A2 (xx)	2000-01-21
HRP990193B1 (en)	2003-08-31
AU753820B2 (en)	2002-10-31
AP9901579A0 (en)	1999-06-30
MA26647A1 (fr)	2004-12-20

Publication	Publication Date	Title
SK286245B6 (sk)	2008-06-06	Farmaceutická kompozícia obsahujúca ziprasidon a spôsob výroby veľkých kryštálov monohydrátu hydrochloridu ziprasidonu
US20200375968A1 (en)	2020-12-03	Apixaban formulations
EP2623100B1 (en)	2023-07-05	Preparation for improving solubility of poorly soluble drug
EP1574215B1 (en)	2015-07-15	Solid drug for oral use
US20130084335A1 (en)	2013-04-04	Ivabradine-containing pharmaceutical composition
US20210401748A1 (en)	2021-12-30	Powder for oral suspension containing lamotrigine
US20100034885A1 (en)	2010-02-11	Formulations containing glimepiride and/or its salts
CN109260207A (zh)	2019-01-25	嘧啶二酮衍生物化合物的制剂
US20220323358A1 (en)	2022-10-13	Powder for oral suspension containing tadalafil
US12129238B2 (en)	2024-10-29	Crystalline form of propoxazepam, the method of its making and use as medicinal agent
AU2017228681B2 (en)	2019-07-18	Apixaban formulations
MXPA99005524A (en)	2000-07-01	Ziprasid formulations
US20050129768A1 (en)	2005-06-16	Pharmaceutical formulation containing an LTB4-antagonist, as well as processes for the preparation thereof and the use thereof

Legal Events

Date	Code	Title	Description
2014-03-04	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20130609